Merck, Ablynx ink immunotherapy deal

Share this content:

Merck and Belgium's Ablynx have signed their second collaboration and licensing deal. Ablynx announced the $27-million partnership Monday. The agreement focuses on nanobodies that can be deployed for immuno-oncology treatments. The three-year research agreement also promises up to $14.5 million in research funding and royalties that could reach $2.3 billion.

Share this content:
Scroll down to see the next article